Rapport Therapeutics, Inc. RAPP Payments For Repurchase Of Unvested Restricted Common Stock
Payments For Repurchase Of Unvested Restricted Common Stock at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rapp:PaymentsForRepurchaseOfUnvestedRestrictedCommonStock.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s payments for repurchase of unvested restricted common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s payments for repurchase of unvested restricted common stock?
- Rapport Therapeutics, Inc. (RAPP) reported payments for repurchase of unvested restricted common stock of $5K in Q1 2026.
- How has Rapport Therapeutics, Inc.'s payments for repurchase of unvested restricted common stock changed year-over-year?
- Rapport Therapeutics, Inc.'s payments for repurchase of unvested restricted common stock increased by 400.0% year-over-year, from $1K to $5K.
- What does payments for repurchase of unvested restricted common stock mean?
- Reflects cash outflows used to repurchase unvested restricted common stock, typically occurring when employees leave the company before their equity awards have fully vested. This activity represents a return of equity to the company's treasury. It is a minor component of financing activities related to employee compensation management.